Gibson, Dunn & Crutcher advised 89bio, Inc. on the offering, and Cooley advised the underwriters. 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced the...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Jade Biosciences on the transaction, and Cooley advised the placement agents; while Goodwin Procter advised Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Sidley Austin is advising GlycoMimetics, Inc. on the transaction, and Gibson, Dunn & Crutcher is advising Crescent Biopharma, Inc. GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Fairmount Funds on the deal. Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical company, announced the pricing...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Rose advised Sixth Street. Arrowhead...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher advised Esperion Therapeutics, Inc. on the deal. Esperion Therapeutics, Inc. (Nasdaq: ESPR) announced that it has entered into a Royalty Purchase Agreement...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher represented XOMA Corporation in the transaction, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Daré. XOMA Corporation (NASDAQ: XOMA) announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising ARCA biopharma, Inc. on the transaction, while Gibson, Dunn & Crutcher is advising Oruka Therapeutics and Cooley is advising...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher represented Apogee Therapeutics, Inc. in the offering, and Cooley represented the underwriters. Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company, announced the...
You must be a Standard 1 Year member to access this content.
XOMA was represented by Gibson, Dunn & Crutcher LLP. XOMA Corporation (NASDAQ: XOMA) announced it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for a...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP represented Dianthus Therapeutics, Inc. on the placement. Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised XOMA Corporation on the expansion of its commercial royalty and milestone portfolio with the acquisition of an economic interest in...
You must be a Standard 1 Year member to access this content.
